Results 41 to 50 of about 177,264 (261)

Cardiovascular Effects of Phosphodiesterase Type 5 Inhibitors

The Journal of Sexual Medicine, 2009
ABSTRACT Introduction Phosphodiesterase type 5 (PDE5) inhibitors are widely used as first-line therapy for erectile dysfunction (ED). Their efficacy and safety combined with an increasing understanding of cyclic guanosine monophosphate (cGMP)-regulated mechanisms have triggered a number of attempts to
Charalambos, Vlachopoulos, Nikolaos, Ioakeimidis, Konstantinos, Rokkas, Christodoulos, Stefanadis   +3 more
openaire   +4 more sources

Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie's Disease.

Journal of Sexual Medicine, 2020
BACKGROUND Myofibroblast transformation is a key step in the pathogenesis of Peyronie's disease (PD). Phosphodiesterase type 5 inhibitors (PDE5is) and selective estrogen receptor modulators (SERMs) can prevent the formation of fibrosis in in vitro and in 
M. Ilg, S. J. Stafford, M. Mateus, Stephen A. Bustin, Michael J Carpenter, A. Muneer, T. Bivalacqua, D. Ralph, S. Cellek   +8 more
semanticscholar   +1 more source

The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review. [PDF]

, 2017
Agents that augment cerebral blood flow (CBF) could be potential treatments for vascular cognitive impairment. Phosphodiesterase-5 inhibitors are vasodilating drugs established in the treatment of erectile dysfunction (ED) and pulmonary hypertension.
Barrick, TR, Hainsworth, AH, Isaacs, JD, Kruuse, C, Madigan, JB, Moynihan, B, Pauls, MM   +6 more
core   +1 more source

Is phosphodiesterase type 5 inhibitor use associated with condom breakage? [PDF]

, 2009
This is an open access article - Copyright © 2009 by the BMJ Publishing Group Ltd. All rights reserved.We tested the hypothesis that phosphodiesterase type 5 inhibitor (PDE5i) use would be associated with increased likelihood of condom breakage using an
Crosby, RA, Graham, CA, Sanders, SA, Yarber, WL   +3 more
core   +1 more source

Erectile dysfunction in diabetes mellitus: A review

Journal of Diabetology, 2020
The International Diabetes Federation estimates that globally there are 425 million people with diabetes. Estimates of the prevalence of erectile dysfunction (ED) in men with diabetes range from 20% to 85% in different studies.
Deepak K Jumani, Omkar Patil
doaj   +1 more source

Risk of nonarteritic ischaemic optic neuropathy with phosphodiesterase type 5 inhibitors: a systematic review and meta‐analysis

Acta ophthalmologica, 2020
The development of nonarteritic anterior ischaemic optic neuropathy has been described to phosphodiesterase type 5 inhibitors. The aim of this systematic review and meta‐analysis was to assess the risk of nonarteritic anterior ischaemic optic neuropathy ...
A. Penedones, C. Alves, F. Batel Marques
semanticscholar   +1 more source

Selective inhibition of phosphodiesterases 4, 5 and 9 induces HSP20 phosphorylation and attenuates amyloid beta 1-42 mediated cytotoxicity [PDF]

, 2016
Phosphodiesterase (PDE) inhibitors are currently under evaluation as agents that may facilitate the improvement of cognitive impairment associated with Alzheimer's disease. Our aim was to determine whether inhibitors of PDEs 4,5 and 9 could alleviate the
Baillie, George S., Cameron, Ryan T., Day, Jon P., Parachikova, Anna I., Whiteley, Ellanor   +4 more
core   +1 more source

cAMP-Signalling Regulates Gametocyte-Infected Erythrocyte Deformability Required for Malaria Parasite Transmission. [PDF]

, 2015
Blocking Plasmodium falciparum transmission to mosquitoes has been designated a strategic objective in the global agenda of malaria elimination. Transmission is ensured by gametocyte-infected erythrocytes (GIE) that sequester in the bone marrow and at ...
A Dawn, A Heiber, A Merckx, A Pantaleo, A Sudo, AE Bianco, Audrey Lorthiois, Bernina Naissant, C Lavazec, C Lavazec, C Syin, Catherine Lavazec, CJ Taylor, D Yokoyama, DA Baker, David A. Baker, DK Muhia, Dominique Soldati-Favre, Donatella Taramelli, E Farfour, E Lasonder, E Ling, Eloise Thompson, F Hawking, F Silvestrini, F Silvestrini, Florence Breil, Florian Dupuy, G Deplaine, Ghania Ramdani, Gordon Langsley, HM Taylor, I Koshino, J Bain, K Leykauf, Kenneth Vernick, KM Tang, L Chen, L McRobert, L Wentzinger, LK Read, M Aingaran, M Boolell, M Hliscs, M Tiburcio, M Tiburcio, ME Smalley, MJ Lopez-Barragan, MK Dearnley, MW Dixon, N Goto, N Mohandas, Odile Mercereau-Puijalon, QL Fivelman, R Aguilar, R Joice, RE Sinden, RE Sinden, RL Coppel, Ross Cummings, RW Moon, S D'Alessandro, S Kunz, S Sanyal, SM Knebel, SP Davies, SP Kim, T Bousema, T Harrison, T Ono, T Seebeck, W Trager, WB Smith 2nd, Yoann Duffier, Yolanda Corbett   +74 more
core   +9 more sources

Management of erectile dysfunction post-radical prostatectomy [PDF]

, 2014
© 2015 Saleh et al.Radical prostatectomy is a commonly performed procedure for the treatment of localized prostate cancer. One of the long-term complications is erectile dysfunction.
Abboudi, H, Ghazal-Aswad, M, Mayer, EK, Saleh, A, Vale, JA   +4 more
core   +1 more source

APPLICATION OF PHOSPHODIESTERASE TYPE 5 INHIBITORS SILDENAFIL IN PATIENTS WITH PULMONARY HYPERTENSION

Евразийский Кардиологический Журнал, 2015
The key component of the pathogenesis of pulmonary hypertension (PH) is endothelial dysfunction with imbalance between vasodilators and vasoconstrictors and activation of the blood coagulation system.
T. V. Martynyuk, Z. H. Dadacheva, V. M. Paramonov, O. A. Arkhipova, S. N. Nakonechnikov, I. Ye. Chazova   +5 more
doaj   +1 more source